ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "nonsteroidal antiinflammatory drugs (NSAIDs) and spondylarthritis"

  • Abstract Number: 639 • 2018 ACR/ARHP Annual Meeting

    Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?

    Loukianos Couvaras1, Daniel Wendling2, Vanessa Pauly3, Vincent Pradel4, Anna Molto5, Pierre Lafforgue1 and Thao Pham6, 1Rheumatology, Aix-Marseille University, APHM, Marseille, France, 2service de rhumatologie, CHU J Minjoz, Besancon, France, 3Public Health, Aix-Marseille university, AP-HM, Marseille, France, 4Public Health, APHM, Marseille, France, 5Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, 6Rheumatology Department, Aix-Marseille University, APHM, Marseille, France

    Background/Purpose: Good response to NSAIDs is a SpA feature included in classification criteria for axial spondyloarthritis (axSpA). Among patients eligible for a TNF inhibitor (TNFi),…
  • Abstract Number: 1532 • 2013 ACR/ARHP Annual Meeting

    Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis

    Susanne Juhl Pedersen1, Stephanie Wichuk2, Praveena Chiowchanwisawakit3, Robert GW Lambert4 and Walter P. Maksymowych2, 1Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 2Medicine, University of Alberta, Edmonton, AB, Canada, 3Mahidol University, Bangkok, Thailand, 4Radiology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Radiography of the sacroiliac joints (SIJ) in spondyloarthritis (SpA) is a valuable diagnostic tool but is unreliable and unresponsive for assessment of treatment effects.…
  • Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting

    Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis

    J Sieper1, M Rudwaleit1, J Lenaerts2, J Wollenhaupt3, L Myasoutova4, S Park5, Y Song6, R Yao7, M Govoni8, D Chitkara9 and N Vastesaeger10, 1University Clinic Benjamin Franklin, Berlin, Germany, 2Practice Rheumatology, Hasselt, Belgium, 3Schön-Klinik, Hamburg, Germany, 4Kazan State Medical University, Kazan, Russia, 5Catholic University of Korea, Seoul, South Korea, 6Seoul National University, Seoul, South Korea, 7Merck & Co., Inc., Whitehouse Station, NJ, 8MSD Italy, Rome, Italy, 9Merck Sharp & Dohme, Kenilworth, NJ, 10Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology